Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep Dave, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Dipankar Bandyopadhyay, Caryn Weir, Elizabeth B. Collins, Amanda Garnett, Maciej Kmieciak, John D. Roberts, Guillermo Garcia-Manero & Steven Grant. (2021) Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & Lymphoma 62:5, pages 1187-1194.
Read now
Read now
Abdallah Hamze. (2020) How do we improve histone deacetylase inhibitor drug discovery?. Expert Opinion on Drug Discovery 15:5, pages 527-529.
Read now
Read now
Pamela B Allen & Mary Jo Lechowicz. (2018) Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas. Cancer Management and Research 10, pages 6731-6742.
Read now
Read now
Articles from other publishers (47)
Daryl Thompson, Nathan Lawrentschuk & Damien Bolton. (2023) New Approaches to Targeting Epigenetic Regulation in Bladder Cancer. Cancers 15:6, pages 1856.
Crossref
Crossref
Danielle Shafer, Amanda B. Kagan, Michelle A. Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader, Dipankar Bandyopadhyay, Daniel Hudson, Heidi Sankala, Caryn Weir, Jeffrey E. Lancet & Steven Grant. (2023) Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemotherapy and Pharmacology 91:3, pages 281-290.
Crossref
Crossref
Carolyn E. Behrendt, Miguel A. Villalona-Calero, Edward M. Newman & Paul H. Frankel. (2023) Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data. Contemporary Clinical Trials 125, pages 107083.
Crossref
Crossref
Ian M. Bouligny, Keri R. Maher & Steven Grant. (2023) Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Reviews 57, pages 100996.
Crossref
Crossref
Jessica L. Dennison, Hassan Al-Ali, Claude-Henry Volmar, Shaun Brothers, Justin Watts, Claes Wahlestedt & Ines Lohse. (2022) Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients. Cancers 14:17, pages 4094.
Crossref
Crossref
Reema R. Barik & Lokesh Kumar Bhatt. (2021) Emerging epigenetic targets in rheumatoid arthritis. Rheumatology International 41:12, pages 2047-2067.
Crossref
Crossref
Nikolay Toshev, Diana Cheshmedzhieva & Todor Dudev. (2021) Factors governing the affinity and selectivity of histone deacetylase inhibitors for the HDAC8 enzyme active site: Implications for anticancer therapy. Journal of Physical Organic Chemistry 34:12.
Crossref
Crossref
Mahdieh Mehrpouri, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. International Immunopharmacology 100, pages 108114.
Crossref
Crossref
Sunil Kumar, Ravinder Nagpal, Amit Kumar, Muhammad Umer Ashraf & Yong-Soo Bae. (2021) Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia. Biomedicines 9:6, pages 690.
Crossref
Crossref
Ambika Pal, Poulami Tapadar & Ranjana Pal. (2021) Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry 21:9, pages 1141-1150.
Crossref
Crossref
Eunyoung Lee, Youngil Koh, Junshik Hong, Hyeon-Seok Eom & Sung-Soo Yoon. (2021) Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. Journal of Korean Medical Science 36:13.
Crossref
Crossref
Feng Li, Jing Zhang, Chao Ma, Ziqian Wang, Yinhua Li, Jimin Zhao & Kangdong Liu. (2020) Targeting Epigenetic Aberrations in Esophageal Squamous Cell Carcinoma. Current Pharmacology Reports 6:6, pages 415-428.
Crossref
Crossref
Vikas Madan & H. Phillip Koeffler. (2020) Differentiation therapy of myeloid leukemia: four decades of development. Haematologica, pages 1-13.
Crossref
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini & Riccardo Petrelli. (2020) Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:15, pages 2449-2493.
Crossref
Crossref
Basheerulla Shaik, Tabassum Zafar & Satya P. Gupta. (2020) Recent Studies on HDAC Inhibitors Acting against Prostate Cancer. Current Enzyme Inhibition 16:1, pages 74-89.
Crossref
Crossref
San José-Enériz, Gimenez-Camino, Agirre & Prosper. (2019) HDAC Inhibitors in Acute Myeloid Leukemia. Cancers 11:11, pages 1794.
Crossref
Crossref
Yong-Tao Duan, Chetan B. Sangani, Wei Liu, Kunjal V. Soni & Yongfang Yao. (2019) New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics. Current Topics in Medicinal Chemistry 19:12, pages 972-994.
Crossref
Crossref
Stefania Crisci, Filomena Amitrano, Mariangela Saggese, Tommaso Muto, Sabrina Sarno, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Massimiliano Berretta & Raffaele Di Francia. (2019) Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina 55:8, pages 414.
Crossref
Crossref
Lambert, Alioui, Jambon, Depauw, Van Seuningen & David-Cordonnier. (2019) Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia.. Cancers 11:6, pages 837.
Crossref
Crossref
Konstantinos Dimopoulos & Kirsten Grønbæk. (2019) Epigenetic therapy in hematological cancers. APMIS 127:5, pages 316-328.
Crossref
Crossref
Sina Jostes, Daniel Nettersheim & Hubert Schorle. (2019) Epigenetic drugs and their molecular targets in testicular germ cell tumours. Nature Reviews Urology 16:4, pages 245-259.
Crossref
Crossref
Deyu Huang, LuQing Cui, Saeed Ahmed, Fatima Zainab, Qinghua Wu, Xu Wang & Zonghui Yuan. (2019) An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs. Food and Chemical Toxicology 123, pages 574-594.
Crossref
Crossref
Rekha Sangwan, Remya Rajan & Pintu Kumar Mandal. (2018) HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European Journal of Medicinal Chemistry 158, pages 620-706.
Crossref
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Crossref
Yi Liao, Liping Xu, Siyu Ou, Holly Edwards, Daniel Luedtke, Yubin Ge & Zhihui Qin. (2018)
H
2
O
2
/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells
. ACS Medicinal Chemistry Letters 9:7, pages 635-640.
Crossref
Crossref
Mélanie Lambert, Samy Jambon, Sabine Depauw & Marie-Hélène David-Cordonnier. (2018) Targeting Transcription Factors for Cancer Treatment. Molecules 23:6, pages 1479.
Crossref
Crossref
Yoosup Chang, Hyejin Park, Hyun-Jin Yang, Seungju Lee, Kwee-Yum Lee, Tae Soon Kim, Jongsun Jung & Jae-Min Shin. (2018) Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature. Scientific Reports 8:1.
Crossref
Crossref
Desmond O. Acheampong, Christian K. Adokoh, Du-Bois Asante, Ernest A. Asiamah, Prince A. Barnie, Dan O.M. Bonsu & Foster Kyei. (2018) Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomedicine & Pharmacotherapy 97, pages 225-232.
Crossref
Crossref
Zhong‑Tian Bai, Bing Bai, Jun Zhu, Cui‑Xia Di, Xun Li & Wen‑Ce Zhou. (2017) Epigenetic actions of environmental factors and promising drugs for cancer therapy (Review). Oncology Letters.
Crossref
Crossref
Tan Boon Toh, Jhin Jieh Lim & Edward Kai-Hua Chow. (2017) Epigenetics in cancer stem cells. Molecular Cancer 16:1.
Crossref
Crossref
Y. Lun, J.-j. Yang & Y. Wu. (2017) Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. Journal of Clinical Pharmacy and Therapeutics 42:6, pages 786-789.
Crossref
Crossref
Emanuely Silva Chrun, Filipe Modolo & Filipe Ivan Daniel. (2017) Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathology - Research and Practice 213:11, pages 1329-1339.
Crossref
Crossref
Rizwan Ahmad, Balawant Kumar, Kaichao Pan, Punita Dhawan & Amar B. Singh. (2017) HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation. Oncotarget 8:50, pages 87718-87736.
Crossref
Crossref
Robert H. Berndsen, U. Kulsoom Abdul, Andrea Weiss, Marloes Zoetemelk, Marije T. te Winkel, Paul J. Dyson, Arjan W. Griffioen & Patrycja Nowak-Sliwinska. (2017) Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis 20:2, pages 245-267.
Crossref
Crossref
Eytan SteinKatharine Yen. (2017) Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. Annual Review of Cancer Biology 1:1, pages 379-401.
Crossref
Crossref
Peter Campbell & Christan M Thomas. (2016) Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Journal of Oncology Pharmacy Practice 23:2, pages 143-147.
Crossref
Crossref
Xiaoyan Qiu, Xiong Xiao, Nan Li & Yuemin Li. (2017) Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry 72, pages 60-72.
Crossref
Crossref
Elisabetta Fratta, Barbara Montico, Aurora Rizzo, Francesca Colizzi, Luca Sigalotti & Riccardo Dolcetti. (2016) Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget 7:35, pages 57327-57350.
Crossref
Crossref
Kapil N. Bhalla & Warren Fiskus. (2016) NEDD8 and HDACs: promising cotargets in AML. Blood 127:18, pages 2168-2170.
Crossref
Crossref
Giedrė Valiulienė, Gražina Treigytė, Jūratė Savickienė, Dalius Matuzevičius, Milda Alksnė, Rasa Jarašienė-Burinskaja, Virginija Bukelskienė, Dalius Navakauskas & Rūta Navakauskienė. (2016) Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy. Biomedicine & Pharmacotherapy 79, pages 62-70.
Crossref
Crossref
S Baig, I Seevasant, J Mohamad, A Mukheem, H Z Huri & T Kamarul. (2016) Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?. Cell Death & Disease 7:1, pages e2058-e2058.
Crossref
Crossref
Xuben Hou, Jintong Du, Renshuai Liu, Yi Zhou, Minyong Li, Wenfang Xu & Hao Fang. (2015) Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8. Journal of Chemical Information and Modeling 55:4, pages 861-871.
Crossref
Crossref
Olatoyosi Odenike, Anna Halpern, Lucy A. Godley, Jozef Madzo, Theodore Karrison, Margaret Green, Noreen Fulton, Ryan J. Mattison, Karen. W. L. Yee, Meghan Bennett, Gregory Koval, Gregory Malnassy, Richard A. Larson, Mark J. Ratain & Wendy Stock. (2014) A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs 33:2, pages 371-379.
Crossref
Crossref
Madhusoodanan Mottamal, Shilong Zheng, Tien Huang & Guangdi Wang. (2015) Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents. Molecules 20:3, pages 3898-3941.
Crossref
Crossref
Nicola Chessum, Keith Jones, Elisa Pasqua & Michael Tucker. 2015.
1
63
.
M Ciechomska, J M van Laar & S O'Reilly. (2014) Emerging role of epigenetics in systemic sclerosis pathogenesis. Genes & Immunity 15:7, pages 433-439.
Crossref
Crossref